Gastric Carcinoma Clinical Trials

15 recruiting

Gastric Carcinoma Trials at a Glance

35 actively recruiting trials for gastric carcinoma are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 8 trials, with the heaviest enrollment activity in Hangzhou, Oklahoma City, and St Louis. Lead sponsors running gastric carcinoma studies include National Cancer Institute (NCI), Jichao Qin, and Mayo Clinic.

Browse gastric carcinoma trials by phase

Treatments under study

About Gastric Carcinoma Clinical Trials

Looking for clinical trials for Gastric Carcinoma? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastric Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastric Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 35 trials

Recruiting
Not Applicable

The Vanguard Study: Testing a New Way to Screen for Cancer

Breast CarcinomaOvarian CarcinomaBladder Carcinoma+8 more
National Cancer Institute (NCI)24,000 enrolled37 locationsNCT06995898
Recruiting

Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis

Gastric CarcinomaIntestinal MetaplasiaGastritis Chronic+1 more
Yongquan Shi450 enrolled1 locationNCT07542652
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Phase 1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI)48 enrolled1 locationNCT06364410
Recruiting
Not Applicable

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Esophageal CarcinomaGastric CarcinomaGastroesophageal Junction Carcinoma+7 more
Alliance for Clinical Trials in Oncology420 enrolled287 locationsNCT07283939
Recruiting
Phase 3

Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)

Advanced Gastric Carcinoma
Asan Medical Center330 enrolled1 locationNCT05226169
Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Phase 1

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

Colorectal CarcinomaGastric CarcinomaPancreatic Ductal Adenocarcinoma
Boehringer Ingelheim135 enrolled3 locationsNCT06882746
Recruiting
Not Applicable

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

Gastric Carcinoma
City of Hope Medical Center240 enrolled1 locationNCT06408220
Recruiting

The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy

Gastric Carcinoma
Jichao Qin400 enrolled1 locationNCT07139418
Recruiting
Phase 3

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Gastric Carcinoma
RemeGen Co., Ltd.555 enrolled1 locationNCT07315750
Recruiting
Phase 2

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Locally Advanced Hepatocellular CarcinomaLocally Advanced Gastric CarcinomaAdvanced Biliary Tract Carcinoma+7 more
OHSU Knight Cancer Institute66 enrolled1 locationNCT05705492
Recruiting
Early Phase 1

PET-imaging of Two Vartumabs in Patients With Solid Tumors

Breast CancerBladder CarcinomaEsophageal Carcinoma+11 more
Var2 Pharmaceuticals32 enrolled1 locationNCT06645808
Recruiting
Phase 1

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Gastroesophageal Junction AdenocarcinomaClinical Stage IV Gastric Cancer AJCC v8Metastatic Gastric Carcinoma+2 more
Mayo Clinic15 enrolled1 locationNCT05802056
Recruiting
Not Applicable

Intravital Microscopy in Human Solid Tumors

Malignant Brain NeoplasmMalignant Solid NeoplasmAnatomic Stage IV Breast Cancer AJCC v8+20 more
Mayo Clinic85 enrolled1 locationNCT03823144
Recruiting
Phase 1

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Malignant Uterine NeoplasmPeritoneal CarcinomatosisClinical Stage IV Gastric Cancer AJCC v8+24 more
City of Hope Medical Center49 enrolled3 locationsNCT04329494
Recruiting
Phase 2

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Metastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Gastric Adenocarcinoma+10 more
Memorial Sloan Kettering Cancer Center37 enrolled7 locationsNCT06251973
Recruiting
Not Applicable

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

Metastatic Gastroesophageal Junction AdenocarcinomaMetastatic Hepatocellular CarcinomaStage IV Hepatocellular Carcinoma AJCC v8+41 more
University of California, San Francisco28 enrolled2 locationsNCT04221893